Helmholtz Centre for Infection Research   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Braunschweig Germany (1965)

Organization Overview

First Clinical Trial
2014
NCT03361878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Helmholtz-Gemeinschaft Deutscher Forschungszentren, Germany | Helmholtz-Zentrum für Umweltforschung - UFZ | Helmholtz Zentrum München

Active Ingredients

Drugs in Phase 4 Trials (1)

metformin (glucophage) (1 trial)

Drugs in Phase 2 Trials (2)

bevacizumab-irdye800cw (1 trial)

insulin human (humulin) (1 trial)

Drugs in Phase 1 Trials (2)

aIIV-B (HepliSav B) (1 trial)

contraloid (2 trials)

Drugs in Other Trials (3)

bifidobacterium infantis (1 trial)

inactivated influenza vaccine (1 trial)

inulin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Barrett Esophagus (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Esophageal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 8